Bionyra Pharma
Updated: August 03, 2026
Founder - Frédéric Marrache
Country: France | Funding: $165M (+)
Founded: 2025
Website: https://bionyra.com
Bionyra advances antibodies aimed at diseases with unmet need despite currently available treatments, including atopic dermatitis and inflammatory bowel disease (IBD). In particular, Bionyra licensed the ex-China rights to BYN-001 from New Jersey-based NovaRock Biotherapeutics. The monoclonal antibody targets the IL-25 pathway, has half-life extension (HLE) technology and is at the IND filing stage for atopic dermatitis, according to the company.
Founded: 2025
Website: https://bionyra.com
Bionyra advances antibodies aimed at diseases with unmet need despite currently available treatments, including atopic dermatitis and inflammatory bowel disease (IBD). In particular, Bionyra licensed the ex-China rights to BYN-001 from New Jersey-based NovaRock Biotherapeutics. The monoclonal antibody targets the IL-25 pathway, has half-life extension (HLE) technology and is at the IND filing stage for atopic dermatitis, according to the company.
